Phase 3 Efficacy and Safety of Abrocitinib in Adults with Moderate-to-Severe Atopic Dermatitis After Switching from Dupilumab (JADE EXTEND).

• Results Overview

  Abrocitinib was effective in treating moderate-to-severe eczema in patients who had previously used dupilumab, regardless of whether they had responded well to dupilumab or not. The medication showed good results in improving both skin symptoms and itch.

• Study Summary

  Num Participants:

  None

  Study Type:

  Observational

  Control Group:

  None

  Efficacy End Points Treatment:

  {'EASI-75 200mg': 93.5, 'EASI-75 100mg': 90.2, 'PP-NRS4 200mg': 89.7, 'PP-NRS4 100mg': 81.6}

  Efficacy End Points Control:

  None

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected
  Nasopharyngitis	Low
  Nausea	Low
  Acne	Low
  Headache	Low

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected